Microbiome related patent filings decreased in the pharmaceutical industry in Q2 2023
Notably, the number of microbiome-related patent applications in the pharmaceutical industry was 102 in Q2 2023, versus 125 in the prior quarter.
The top five companies accounted for 20% of patenting activity
Analysis of patenting activity by companies shows that DSM-Firmenich filed the most microbiome patents within the pharmaceutical industry in Q2 2023. The company filed 8 microbiome-related patents in the quarter, compared with 9 in the previous quarter. It was followed by Givaudan with 6 microbiome patent filings, AOBiome (2 filings), and French National Institute of Health and Medical Research (2 filings) in Q2 2023.
Patenting activity was driven by the US with a 43% share of total patent filings
The largest share of microbiome related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 43%, followed by Japan (10%) and China (8%). The share represented by the US was 2% higher than the 42% share it accounted for in Q1 2023.
For further understanding of GlobalData’s Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
Source link
#Microbiome #related #patent #filings #decreased #pharmaceutical #industry
